Although there are indications that BRCA2-mutated breast cancers and BRCA2-likeCGH tumors are slightly more sensitive to standard chemotherapy than breast cancers not having these features [17,29,30], here we have shown that patients with BRCA2-likeCGH tumors, just like patients with BRCA1-likeCGH tumors, derive substantial more benefit from intensified, DNA DSB-inducing agents (CTC) than from conventional FE90C. Unfortunately, we could not determine whether a lower, non-myeloablative dose of CTC would also have resulted in a similarly improved outcome. Here, BRCA2 is linked to breast carcinoma.